Persistent IL-10 production is required for glioma growth suppressive activity by Th1-directed effector cells after stimulation with tumor lysate-loaded dendritic cells

被引:32
作者
De Vleeschouwer, Steven
Lopes, Isabel Spencer
Ceuppens, Jan L.
Van Gool, Stefaan W.
机构
[1] Catholic Univ Louvain, Expt Immunol Lab, B-3000 Louvain, Belgium
[2] Univ Hosp Gasthuisberg, Dept Neurosurg, B-3000 Louvain, Belgium
[3] Univ Hosp Gasthuisberg, Dept Pediat Hematooncol, B-3000 Louvain, Belgium
关键词
dendritic cell; glioblastoma; immunotherapy; interleukin-10; Th1; response;
D O I
10.1007/s11060-007-9362-y
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Injection of dendritic cells (DC) pulsed with tumor antigens is a novel treatment strategy against malignancies, and aims to elicit anti-tumoral cell-mediated immune responses. We studied the in vitro proliferative responses and cytokine production in T cell cultures after 2 stimulations with autologous DC loaded with tumor lysates derived from glioblastoma multiforme (GBM) cells in the presence of recombinant interleukin (rIL)-6/rIL-12 in the first, and rIL-2/rIL-7 in the second stimulation. After the second stimulation, T cells were co-cultured with glioblastoma (GBM) cells and tumor growth suppression by T cells was assessed using a MTT assay. Although loaded DC induced a significant shift towards T helper cell type 1 (Th1) cytokine production as compared to unloaded DC, persistent interleukin (IL)-10 production by T cells both at the end of 2 stimulations with loaded DC and during the effector phase was also required for their tumor suppressive activity. A stronger glioma growth suppressive activity by T cells stimulated with tumor lysate-loaded DC than by control T cells, cultured with unloaded DC, was seen only if the relative IL-10 production after two stimulations with loaded DC was at least 40% of the IL-10 production after two stimulations with unloaded DC. If less than 40% IL-10 was produced in the experimental condition compared to the control condition, T cells also lost their tumor growth suppressive activity. Addition of rIL-10 during stimulation increased the suppressive activity on tumor cell viability and interferon (IFN)-gamma production by T cells that showed Th1 response upon stimulation with loaded DC. The data point towards the production of both IFN-gamma and IL-10 by responding effector T cells, and towards an immune modulatory rather than immune suppressive role of IL-10 to generate anti-tumoral effector T cells against GBM.
引用
收藏
页码:131 / 140
页数:10
相关论文
共 45 条
[1]   Mechanisms of interleukin-10-mediated immune suppression [J].
Akdis, CA ;
Blaser, K .
IMMUNOLOGY, 2001, 103 (02) :131-136
[2]  
Berman RM, 1996, J IMMUNOL, V157, P231
[3]   IL-10 gene transfer to intracranial 9L glioma: tumor inhibition and cooperation with IL-2 [J].
Book, AA ;
Fielding, KE ;
Kundu, N ;
Wilson, MA ;
Fulton, AM ;
Laterra, J .
JOURNAL OF NEUROIMMUNOLOGY, 1998, 92 (1-2) :50-59
[4]   Effects of co-stimulation by CD58 on human T cell cytokine production: a selective cytokine pattern with induction of high IL-10 production [J].
Bullens, DMA ;
Rafiq, K ;
Charitidou, L ;
Peng, XH ;
Kasran, A ;
Warmerdam, PAM ;
Van Gool, SW ;
Ceuppens, JL .
INTERNATIONAL IMMUNOLOGY, 2001, 13 (02) :181-191
[5]   Type 1 and Type 2: A fundamental dichotomy for all T-cell subsets [J].
Carter, LL ;
Dutton, RW .
CURRENT OPINION IN IMMUNOLOGY, 1996, 8 (03) :336-342
[6]  
Chaux P, 1998, INT J CANCER, V77, P538, DOI 10.1002/(SICI)1097-0215(19980812)77:4<538::AID-IJC11>3.3.CO
[7]  
2-2
[8]   Uptake and presentation of malignant glioma tumor cell lysates by monocyte-derived dendritic cells [J].
De Vleeschouwer, S ;
Arredouani, M ;
Adé, M ;
Cadot, P ;
Vermassen, E ;
Ceuppens, JL ;
Van Gool, SW .
CANCER IMMUNOLOGY IMMUNOTHERAPY, 2005, 54 (04) :372-382
[9]   Transient local response and persistent tumor control in a child with recurrent malignant glioma: treatment with combination therapy including dendritic cell therapy - Case report [J].
De Vleeschouwer, S ;
Van Calenbergh, F ;
Demaerel, P ;
Flamen, P ;
Rutkowski, S ;
Kaempgen, E ;
Wolff, JE ;
Plets, C ;
Sciot, R ;
Van Gool, SW .
JOURNAL OF NEUROSURGERY, 2004, 100 (05) :492-497
[10]   Tc1 and Tc2 effector cell therapy elicit long-term tumor immunity by contrasting mechanisms that result in complementary endogenous type 1 antitumor responses [J].
Dobrzanski, MJ ;
Reome, JB ;
Hollenbaugh, JA ;
Dutton, RW .
JOURNAL OF IMMUNOLOGY, 2004, 172 (03) :1380-1390